To date, subgroup analyses of pivotal clinical trials have shown that current ICI combination regimens have some effectiveness in NSCLC patients with LKB1 or KEAP1 inactivation compared to standard platinum doublet chemotherapies (52, 57, 67, 69, 70). This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.